Chaney C Kalinich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2238750/publications.pdf

Version: 2024-02-01

471061 5,449 24 17 citations h-index papers

g-index 46 46 46 12225 docs citations times ranked citing authors all docs

713013

21

#	Article	IF	CITATIONS
1	Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infectious Diseases, The, 2022, 22, e52-e58.	4.6	59
2	Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient. Journal of Infectious Diseases, 2022, 225, 374-384.	1.9	7
3	A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. Journal of Experimental Medicine, 2022, 219, .	4.2	46
4	Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. Cell Reports Medicine, 2022, 3, 100583.	3.3	101
5	Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents. JAMA Network Open, 2022, 5, e220935.	2.8	20
6	Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. Med, 2022, 3, 325-334.e4.	2.2	60
7	Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and lota. Communications Biology, 2022, 5, 439.	2.0	9
8	SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. Med, 2021, 2, 263-280.e6.	2.2	211
9	Abstract S03-03: Cancer patients display diminished viral RNA clearance and altered T cell responses during SARS-CoV-2 infection. , 2021, , .		O
10	Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient., 2021,,.		3
11	Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva. Emerging Infectious Diseases, 2021, 27, 1146-1150.	2.0	61
12	Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. Cell, 2021, 184, 2595-2604.e13.	13.5	113
13	Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine, 2021, 27, 1178-1186.	15.2	183
14	Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2. PLoS Biology, 2021, 19, e3001236.	2.6	200
15	Lying in wait: the resurgence of dengue virus after the Zika epidemic in Brazil. Nature Communications, 2021, 12, 2619.	5.8	43
16	Diverse functional autoantibodies in patients with COVID-19. Nature, 2021, 595, 283-288.	13.7	619
17	Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies. PLoS Biology, 2021, 19, e3001333.	2.6	133

#	Article	lF	CITATIONS
19	362. Saliva as a Reliable Sample Type for Mass SARS-CoV-2 Testing Strategies. Open Forum Infectious Diseases, 2021, 8, S284-S284.	0.4	O
20	Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature, 2020, 588, 315-320.	13.7	1,035
21	Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets. Nature Microbiology, 2020, 5, 1299-1305.	5.9	661
22	Real-time public health communication of local SARS-CoV-2 genomic epidemiology. PLoS Biology, 2020, 18, e3000869.	2.6	15
23	Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. New England Journal of Medicine, 2020, 383, 1283-1286.	13.9	823
24	Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States. Cell, 2020, 181, 990-996.e5.	13.5	321